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Background: For the effective bone regeneration with appropriate pathological/physiological properties, a variety
of bone fillers have been adapted as a therapeutic treatment. However, the development of ideal bone fillers is still
remained as a big challenge in clinical practice. The main aims of this study are i) fabrication of a highly porous PCL
beads; and ii) the estimation of the potential use of the porous PCL beads as a bone filler through preliminary
animal study.
Results: The porous PCL beads with size range of 53 ~ 600 μm (425 ~ 500 μm dominantly) are fabricated by a
spray/precipitation method using a double nozzle spray and PCL solution (in tetraglycol). The PCL beads show
highly porous inner pore structure and the pores are interconnected with outer surface pores. For the preliminary
animal study, we recognize that the porous PCL bead can induce the new bone formation from the outer surface
of bone defect toward the bone marrow cavity through the bead matrix.
Conclusions: From the preliminary results, we can suggest that the highly porous PCL beads may be a promising
candidate as a bone filler (scaffolding matrix) for the effective bone regeneration.
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Although an injury bone can be reconstructed spontan-
eously, large bone defects created by trauma, tumor re-
section, corrective osteotomy, and congenital deformity
are considered as a notable challenge for orthopedic and
oral/maxiallofacial surgeons [1]. For the effective bone
regeneration with appropriate pathological/physiological
properties, a variety of bone grafts including biological
and synthetic biomaterials have been utilized as a thera-
peutic treatment. The biological grafts (autograft and
allograft) are commonly used as a first line therapy for
large-sized bone defect, but insufficient donor materials,
inevitable donor site morbidity, risk of infection (auto-
graft); and risk of immune response/disease transmission
(allograft) remain as significant limitations in the clinical* Correspondence: seheangoh@dankook.ac.kr
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unless otherwise stated.practice [2-4]. To solve the limitations, ceramic-based
materials with similar mineral constituent of bone, such
as hydroxyapatite (HA) and tri-calcium phosphate (TCP)
have been utilized for the effective bone regeneration due
to their biocompatibility, non-immunogenecity, osteocon-
ductivity, bonding affinity with host bone, etc. [4-8]. How-
ever, their low reliability (i.e., weak mechanical strengths
and high fragile failure rate) in wet environment which
leads to difficulty for load-bearing applications and long-
term degradation rate which can prohibit new bone
growth into the defect site are considered as a limitation
for clinical applications [5,9,10]. Recently, US Food and
Drug Administration (FDA) approved biodegradable poly-
mers [e.g., poly(glycolic acid) (PGA), poly(lactic acid)
(PLA) and poly(lactic acid-co-glycolic acid) (PLGA), poly
(ε-caprolactone) (PCL), polydioxanone (PDO)] with bio-
compatibility, predictable degradation rate and control-
lable mechanical properties are gained increasing interest
as alternative matrices for bone regeneration [11]. Among
them, the PCL is considered as a more promising matrix
for bone regeneration compared to the other biodegradabled. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain










Figure 1 Schematic diagram showing the porous PCL beads
fabrication procedure.
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during degradation, flexibility (vs. PGA, PLA, PLGA);
and relatively long-term structural stability which can
provide a frame work during bone regeneration (vs. PGA,
PLGA, PDO). Low et al. [12] demonstrated that the PCL
matrix can allow biomimetic environment for the initial
blood coagulation, cell infiltration, new blood vessel for-
mation, and effective long-term osteogenesis. Moreover,
Schantz et al. [13] reported that the PCL matrix is well
tolerated in vivo and integrated with the host bone, sug-
gesting that the PCL matrix may be a suitable graft for
bone regeneration. Nevertheless the encouraging results,
the use of PCL matrix as a bone filler is still limited, prob-
ably due to the concern about long-term remaining at
applied site of dense PCL matrix which may prevent new
bone formation. However, we expected that the highly
porous PCL matrix may allow an appropriate environ-
ment for initial bone growth (by structural stability),
accelerated degradation (by large surface area), sustained
delivery of bioactive molecules (by high porosity), and thus
become a good candidate as a bone filler.
Therefore, the main aims of this study are i) fabrica-
tion of a highly porous PCL bead; and ii) the estimation
of the potential use of the porous PCL bead as a bone filler
through preliminary animal study. To achieve this goal,
porous PCL beads are fabricated by a spray/precipitation
method using a double nozzle spray and PCL solution (in
tetraglycol). The tetraglycol which is frequently utilized in
parenteral delivery [14-16] is used as a nontoxic solvent
for PCL. The preliminary animal study (femur defect rat
model) to estimate the bone regeneration behavior by the
porous PCL bead is also investigated.
Method
Materials
PCL (Mw 80,000 Da) and tetraglycol (glycofurol) as a
nontoxic solvent for PCL were purchased from Sigma-
Aldrich (USA). All other chemicals were analytical grade
and were used as received. Ultrapure grade water (>18
mΩ) was purified using a Milli-Q purification system
(Millipore Co., USA). For animal study, the porous PCL
beads were sterilized by ethylene oxide (EO).
Preparation of porous PCL beads
Porous PCL beads were simply prepared by spray/
precipitation method using double nozzle spray. PCL
pellets were dissolved in tetraglycol at 90°C (15 wt%),
and the PCL solution was immediately transferred in a
10 mL syringe. The warm solution was sprayed through a
double nozzle spray with N2 purging of 2.5 L/min (outer
nozzle) into 50% ethanol solution (coagulation solution)
to induce the solidification (precipitation) of PCL solution
(Figure 1). Feeding rate of the solution was fixed to
60 mL/h (inner nozzle, using syringe pump). The syringeand double nozzle spray were heated (90°C) using a heat-
ing system equipped with heating tape (PID temperature
controller, Model, TC130P; heating tape, Model, HT2510;
Misung Scientific, Korea) to prevent precipitation of PCL
during the process. The distance of tip-to-coagulation
solution was 20 cm. The precipitated PCL beads were
maintained at coagulation solution for 6 hrs, then the PCL
beads were washed out in excess water for 24 hrs to re-
move residual tetraglycol and ethanol. The PCL beads
were obtained by centrifugation and dried in a vacuum
oven overnight, and the beads were separated in dif-
ferent size ranges (53 ~ 100, 100 ~ 200, 200 ~ 300, 300 ~
425, 425 ~ 500, 500 ~ 600 μm) using standard testing
sieves (Chunggye Industrial Co., Korea).
Characterization of porous PCL beads
Morphology observation and porosity measurement
The morphology of prepared porous PCL beads was ob-
served by a field emission scanning electron microscope
(FE-SEM; Model S-4300, Hitachi, Japan). The cross-
sectional specimen was prepared by cutting them using
a blade after being frozen in liquid nitrogen. The porosity
of the PCL beads was estimated using mercury porosime-
try (Poresizer 9320; Micromeritics, USA). To determine
the porosity, it was assumed that the surface tension of
mercury is 480 dyne/cm [17].
Preliminary animal study
Sprague–Dawley (SD) rats (~250 g) were selected as an
animal model to estimate the bone reconstruction po-
tential by the use of porous PCL beads. The animal study
was permitted from the Animal Care Committee of the
Hannam University in Korea, and all surgical procedures
were performed according to the guidelines. The rats were
completely anesthesized with intramuscular injection of
tiletamine/zolazepam (10 mg/kg; Zoletil 50®, Virbac
Laboratories, France) and 2% xylazine hydrochloride (2 mg/kg;
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The left leg was shaved and the skin surface discontami-
nated with 7% tincture of iodine. The front skin of the
mid-femur in rats was incised straight and longitudinally
at 30 mm in length. After splitting the muscle, the perios-
teum was stripped to expose the femoral bone surface.
Two drill-holes (each hole, ~4 mm in diameter) were cre-
ated through the femoral cortex using a small tungsten
carbide dental bur with a diameter of 0.8 mm in the anter-
ior portion of the diaphysis of one femur (10 mm position
from the knee joint) (Figure 2). The bone defect was pre-
pared with a very gentle surgical technique and continu-
ous internal cooling with physiological saline solution.
Then the porous PCL beads were implanted into the de-
fect, and the wound was closed in two layers using 4–0
vicryl and 4–0 nylon sutures. The blank (w/o any treat-
ment) was also studied as a control group. During surgery
and 24 hrs later, all animals received subcutaneous injec-
tions of antibiotics (sulfadoxin and trimethoprin, 5:1,
15 mg/kg) to minimize the risk of infections. At 4 weeks
after implantation, the rats were sacrificed by an overdose
of CO2 gas. For histological observation, the bone defects
with surrounding femoral bone were harvested, and the
specimens were fixed with 4% formaldehyde and decalci-
fied in 10% formic acid. After dehydration procedure of
the fixed specimens in a graded series of alcohol, the spec-
imens were embedded in paraffin and cut into 5 μm trans-
verse sections in the defects. The sections were stained
with Hematoxyline & eosin (H&E) and Masson’s tri-
chrome (MT) for observation by light microscopy (Model
BX50F4, Olympus). For radiographic evaluation, the tissue
specimens harvested from the femur of rat were frozen,
and placed on an automatic axially-moving turntable to
scan using a micro-computed tomography (μ-CT) system
(Skyscan 1176, Skyscan N.V., Belgium)).
Results and discussion
Preparation and characterization of porous PCL beads
Porous PCL beads were prepared to estimate its feasibil-
ity as an bone filler for the effective bone regeneration.**
Figure 2 Photographs showing the implantation of porous PCL beads iThe PCL is the most commonly utilized biodegradable
polyesters with biocompatibility and predictable degrad-
ation rate for medical applications [18]. Their degrad-
ation is understood as a metabolism via tricarboxylic acid
(TCA) cycle [19]. The porous PCL beads were fabricated
by a simple spray/precipitation method using double
nozzle spray and PCL solution. The gross appearance of
prepared porous PCL beads with different size ranges and
their surface/cross-sectional morphologies observed by
SEM were shown in Figures 3 and 4.
It was observed that the size range of the prepared
porous PCL beads in our procedure [purging rate of N2,
2.5 L/min (outer nozzle) and feeding rate of PCL solu-
tion, 60 mL/h (inner nozzle)] is 53 ~ 600 μm and the
porous PCL beads with size range of 425 ~ 500 μm is
more dominant than other size ranges. Their size distri-
bution also can be controlled by the purging rate of N2
and/or feeding rate of polymer solution [higher N2 pur-
ging rate, smaller size dominantly (lower volume ratio of
polymer solution to N2 gas); higher PCL solution feeding
rate, larger size dominantly (higher volume ratio of poly-
mer solution to N2 gas); not shown data), as expected.
The porous PCL beads exhibited highly porous inner
pore structures and the pores are interconnected with
surface pores. The formation of porous structure can be
understood by phase separation between polymer (PCL)
solution and nonsolvent [solvent (tetraglycol)-nonsolvent
(50% ethanol) exchange] during the precipitation of the
PCL solution in coagulation bath [20]. From the morph-
ology results, we could expect that the highly porous
structure can provide large surface area of PCL matrix
and thus may accelerate the degradation rate which can
allow appropriate space for new bone formation, more-
over the porous beads may be a reservoir of bioactive
molecules for bone regeneration (e.g., drugs, growth fac-
tors, cytokines, etc.). Therefore, we believed that the
porous PCL beads may be a promising matrix for effect-
ive bone regeneration. The porosity of the porous PCL
beads measured using mercury porosimetry were over
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Figure 3 (A) SEM Photographs of the prepared porous PCL beads with different size range (x100) and (B) their distribution expressed
by weight fraction.




Figure 4 SEM Photographs of the surface and cross-sectional view of the PCL beads with size range of 425 ~ 500 μm.






Figure 5 Histological sections of bone defect and surrounding femoral tissue showing the bone regeneration behavior of the control
(blank) and porous PCL beads (*, host bone; arrow, new bone; †, PCL beads; H&E staining, x40).
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Figure 6 Histological sections of bone defect and surrounding femoral tissue showing the bone regeneration behavior of the control
(blank) and porous PCL beads (*, host bone; arrow, new bone; †, PCL beads; Masson’s trichrome staining, x40).
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inary animal study using rat model [21].
Preliminary animal study
A SD rat model was used to estimate the bone regener-




A: Porous PCL bead;
Figure 7 μ-CT images of femoral bone defect showing the mineralize
control (blank) [*, host bone; arrow, regenerated (mineralized) bone].bone defect was chosen as the orthotopic model for this
experiment. Bone defects of ~4 mm diameter were cre-
ated on a femur using a small tungsten carbide dental
bur, and the porous PCL beads were filled into the de-
fect. The blank (w/o any treatment) was also studied as







d bone regeneration behavior of (A) porous PCL beads and (B)
Byun et al. Biomaterials Research 2014, 18:18 Page 7 of 8
http://www.biomaterialsres.com/content/18/1/18were easily applied and formed well-packed structure in
the defect site without floating by bleeding. During the
breeding, all animals remained in sound health and did
not show any wound complications. Figures 5 and 6 show
the histological sections (after H&E and MT staining) to
compare bone reconstruction behavior in the bone defect
filled with and without the porous PCL beads at 4 weeks
after surgery. In the PCL bead group, the new bone was
regenerated from the outer surface of bone defect toward
the bone marrow cavity through the porous PCL beads.
However, in the control (blank) group, the new bone was
only reconstructed at outer surface of bone defect and the
new bone formation in the marrow cavity was not de-
tected. This indicates that the porous PCL bead itself can
provide an appropriate environment for ingrowth of a var-
iety of cells related with bone formation, and thus allow
bone regeneration in the PCL bead matrix. The regener-
ated bone was grown along the porous matrix consisted of
the PCL beads, suggesting that the beads are stably kept
their porous structure without degradation during the
bone regeneration and act as a scaffolding matrix which
can allow the adhesion of bone-related cells and thus im-
prove osteogenesis [22-24]. At 4 weeks after implantation,
the mineralized bone regeneration was also studied using
μ-CT. The growth of mineralized bone tissues begun at
the outer surface of all bone defects (Figure 7), and the
mineralized bone tissue was infiltrated through the PCL
bead matrix. This observation was consistent with the re-
sult of the histological results, showing that the porous
PCL beads can effectively induce the bone regeneration.
On the basis of our findings, we can suggest that the highly
porous PCL beads fabricated by simple spray/precipitation
method may be a candidate as a bone filler for the effective
bone regeneration.
Conclusions
We prepared porous PCL beads by a spray/precipitation
method using a double nozzle spray and PCL solution
(in tetraglycol). It was observed that the size range of
prepared porous PCL beads (purging rate of N2, 2.5 L/min
and feeding rate of PCL solution, 60 mL/hr) is 53 ~
600 μm (dominant size range, 425 ~ 500 μm) and their
size distribution can be controlled by the purging rate of
N2 and/or feeding rate of polymer solution. The porous
PCL beads showed highly porous inner pore structure and
the pores are interconnected with outer surface pores. For
the preliminary animal study, we recognized that the por-
ous PCL bead can induce the new bone formation from
the outer surface of bone defect toward the bone marrow
cavity through the bead matrix. From the preliminary re-
sults, we could suggest that the highly porous PCL beads
may be a promising candidate as a matrix for the bone re-
generation. The long-term studies (i.e., in vivo degradation
rate of the porous PCL beads and bone regeneration/maturation behaviors through the matrix) using a large
animal (porcine) to confirm the potential use of the por-
ous PCL beads as a clinically applicable bone filler are in
progress.
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